» Articles » PMID: 16472586

Hypothalamic-pituitary-gut Axis Dysregulation in Irritable Bowel Syndrome: Plasma Cytokines As a Potential Biomarker?

Overview
Specialty Gastroenterology
Date 2006 Feb 14
PMID 16472586
Citations 213
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Irritable bowel syndrome (IBS) is a functional disorder with an etiology that has been linked to both psychological stress and infection. The primary aim of this study was to examine the hypothalamic-pituitary-adrenal axis in patients with IBS and to relate such response to plasma cytokine profiles.

Methods: A total of 151 subjects, 76 patients and 75 controls, were recruited. The patients with IBS were diagnosed according to Rome II criteria. Forty-nine patients and 48 matched controls had cytokine levels measured, and a subset of 21 patients and 21 controls also underwent a corticotropin-releasing hormone (CRH) stimulation test with plasma levels of adrenocorticotropic hormone (ACTH) and cortisol measured. The remaining 27 patients and 27 controls underwent a dexamethasone (1 mg) challenge.

Results: Cortisol and the proinflammatory cytokines interleukin (IL)-6 (together with its soluble receptor) and IL-8 were elevated in all IBS subgroups (diarrhea predominant, constipated, and alternators), although the elevation was most marked in the constipated subgroup. There was no alteration in the anti-inflammatory cytokine IL-10. Following CRH infusion, an exaggerated release of both ACTH and cortisol was observed in patients with IBS. There was a significant correlation between the ACTH response (deltaACTH) and the IL-6 levels. A similar relationship existed between the deltaACTH/deltacortisol ratio and the IL-6 levels. Dexamethasone suppression of cortisol was similar in patients and controls.

Conclusions: IBS is characterized by an overactivation of the hypothalamic-pituitary-adrenal axis and a proinflammatory cytokine increase.

Citing Articles

Heart rate variability, daily cortisol indices and their association with psychometric characteristics and gut microbiota composition in an Italian community sample.

Ravenda S, Mancabelli L, Gambetta S, Barbetti M, Turroni F, Carnevali L Sci Rep. 2025; 15(1):8584.

PMID: 40074815 PMC: 11903775. DOI: 10.1038/s41598-025-93137-8.


Comparisons of different electrical stimulation modalities for treating visceral pain in a rodent model of irritable bowel syndrome.

Alam M, Zhao T, Wiley J, Chen J Bioelectron Med. 2024; 10(1):27.

PMID: 39523376 PMC: 11552343. DOI: 10.1186/s42234-024-00158-1.


Novel hypothesis and therapeutic interventions for irritable bowel syndrome: interplay between metal dyshomeostasis, gastrointestinal dysfunction, and neuropsychiatric symptoms.

Nakagawa Y, Yamada S Mol Cell Biochem. 2024; .

PMID: 39503802 DOI: 10.1007/s11010-024-05153-3.


Morphological Changes of the Pituitary Gland in Patients with Irritable Bowel Syndrome Using Magnetic Resonance Imaging.

Chaaya J, Abou Chaaya J, Jaafar B, Saab L, Abou Chaaya J, Al Ahmar E J Imaging. 2024; 10(9).

PMID: 39330446 PMC: 11433444. DOI: 10.3390/jimaging10090226.


A meta-analysis of randomized controlled trials evaluating the effectiveness of fecal microbiota transplantation for patients with irritable bowel syndrome.

Wang Y, Hu Y, Shi P BMC Gastroenterol. 2024; 24(1):217.

PMID: 38970007 PMC: 11225114. DOI: 10.1186/s12876-024-03311-x.